Shares of Arbutus Biopharma Corp. (NASDAQ:ABUS) were up 5.1% on Monday . The company traded as high as $3.97 and last traded at $3.93, with a volume of 63,716 shares traded. The stock had previously closed at $3.74.

A number of analysts recently weighed in on ABUS shares. Zacks Investment Research upgraded Arbutus Biopharma Corp. from a “hold” rating to a “buy” rating and set a $6.00 target price for the company in a research report on Monday, April 25th. Wedbush restated an “outperform” rating and issued a $20.00 target price on shares of Arbutus Biopharma Corp. in a research report on Wednesday, May 4th. Leerink Swann restated a “buy” rating and issued a $12.00 target price on shares of Arbutus Biopharma Corp. in a research report on Thursday, May 5th. Finally, Chardan Capital started coverage on Arbutus Biopharma Corp. in a research report on Monday, May 16th. They issued a “sell” rating and a $3.25 target price for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $9.39.

The company’s market capitalization is $214.80 million. The firm’s 50 day moving average is $4.00 and its 200 day moving average is $3.96.

Arbutus Biopharma Corp. (NASDAQ:ABUS) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by $0.36. Analysts forecast that Arbutus Biopharma Corp. will post ($3.35) EPS for the current fiscal year.

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.